Skip to main content
. 2023 Mar 17;12(3):490–501. doi: 10.21037/tcr-22-2478

Table 1. Characteristics of patients in the primary cohort and validation cohort.

Characteristics Primary cohort Validation cohort
Non-PTC (n=157) PTC (n=343) P Non-PTC (n=53) PTC (n=99) P
Age (years), median [IQR] 53.00 [47.00, 59.00] 46.00 [37.00, 54.00] <0.001 48.00 [35.00, 56.00] 47.00 [36.00, 55.00] 0.675
Gender, n (%)
   Male 41 (26.1) 76 (22.2) 0.363 8 (15.1) 18 (18.2) 0.822
   Female 116 (73.9) 267 (77.8) 45 (84.9) 81 (81.8)
Echogenicity, n (%)
   hyperechoic or isoechoic 105 (66.9) 20 (5.8) <0.001 39 (73.6) 9 (9.1) <0.001
   hypoechoic or markedly 52 (33.1) 323 (94.2) 14 (26.4) 90 (90.9)
Margin, n (%)
   Clear 130 (82.8) 63 (18.4) <0.001 47 (88.7) 27 (27.3) <0.001
   Unclear 27 (17.2) 280 (81.6) 6 (11.3) 72 (72.7)
Shape, n (%)
   Regular 124 (79.0) 57 (16.6) <0.001 46 (86.8) 18 (18.2) <0.001
   Irregular 33 (21.0) 286 (83.4) 7 (13.2) 81 (81.8)
Echotexture, n (%)
   Homogeneous 59 (37.6) 7 (2.0) <0.001 20 (37.7) 4 (4.0) <0.001
   Heterogeneous 98 (62.4) 336 (98.0) 33 (62.3) 95 (96.0)
Calcification, n (%)
   No 134 (85.4) 164 (47.8) <0.001 48 (90.6) 34 (34.3) <0.001
   Yes 23 (14.6) 179 (52.2) 5 (9.4) 65 (65.7)
Composition, n (%)
   Cystic or spongiform 82 (52.2) 16 (4.7) <0.001 31 (58.5) 6 (6.1) <0.001
   Solid 75 (47.8) 327 (95.3) 22 (41.5) 93 (93.9)
Tall than wide, n (%)
   <1 140 (89.2) 75 (21.9) <0.001 43 (81.1) 38 (38.4) <0.001
   ≥1 17 (10.8) 268 (78.1) 10 (18.9) 61 (61.6)
TSH (mIU/mL), n (%)
   <2 89 (56.7) 150 (43.7) 0.009 34 (64.2) 52 (52.5) 0.175
   ≥2 68 (43.3) 193 (56.3) 19 (35.8) 47 (47.5)
SII, n (%)
   <439 101 (64.3) 148 (43.1) <0.001 27 (50.9) 54 (54.5) 0.734
   ≥439 56 (35.7) 195 (56.9) 26 (49.1) 45 (45.5)
LMR, n (%)
   <4 45 (28.7) 194 (56.6) <0.001 19 (35.8) 27 (27.3) 0.354
   ≥4 112 (71.3) 149 (43.4) 34 (64.2) 72 (72.7)
TI-RADS, n <0.001 <0.001
   3 102 13 35 3
   4–5 55 330 18 96

P value: two-tailed test, <0.05 were considered statistically significant. PTC, papillary thyroid carcinoma; IQR, interquartile range; TSH, thyrotropin; SII, systemic immune-inflammation index; LMR, lymphocyte-to-monocyte ratio; TI-RADS, Thyroid Imaging Reporting and Data System.